<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="181">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279667</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-109</org_study_id>
    <nct_id>NCT02279667</nct_id>
  </id_info>
  <brief_title>Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093</brief_title>
  <official_title>Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <authority>Portugal: INFARMED, National Authority of Medicines and Health Products, IP</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single centre, open-label, randomised, three-way crossover study in 18 healthy subjects (9
      males and 9 females). The study consisted of three consecutive single-dose treatment periods
      separated by a washout period of 7 days or more. On each treatment period, the volunteers
      received a single dose of BIA 2-093 800 mg, orally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sample size (planned and analyzed): It was planned to have at least 16 healthy subjects
      completed and evaluable. Taking into account the potential occurrence of dropouts, two
      additional subjects were to be recruited and entered the study. Therefore, a total of 18
      subjects were enrolled.

      Diagnosis and main selection criteria: Healthy male or female volunteers aged between 18 and
      45 years, with body mass index between 19 and 28 kg/m2, non-smokers or smoking less than 10
      cigarettes or equivalent per day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cmax - the Maximum Plasma Concentration</measure>
    <time_frame>Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax - the maximum plasma concentration of BIA 2-093 metabolite: BIA 2-005</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - the Time of Occurrence of Cmax</measure>
    <time_frame>Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax - the Time of Occurrence of maximum plasma concentration of BIA 2-093 metabolite: BIA 2-005</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time</measure>
    <time_frame>Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time of BIA 2-093 metabolite: BIA 2-005</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity</measure>
    <time_frame>Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity of BIA 2-093 metabolite: BIA 2-005</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>st period - 16 mL oral suspension 50 mg/mL
nd period - Four 200 mg tablets
rd period - One 800 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>st period - One 800 mg tablet
nd period - 16 mL oral suspension 50 mg/mL
rd period - Four 200 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>st period - Four 200 mg tablets
nd period - One 800 mg tablet
rd period - 16 mL oral suspension 50 mg/mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093</intervention_name>
    <description>oral suspension 50 mg/mL</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>ESL, Eslicarbazepine acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093</intervention_name>
    <description>200 mg tablet</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>ESL, Eslicarbazepine acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093</intervention_name>
    <description>800 mg tablet</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>ESL, Eslicarbazepine acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged between 18 and 45 years, inclusive.

          -  Subjects of body mass index (BMI) between 19 and 28 kg/m2, inclusive.

          -  Subjects who were healthy as determined by pre-study medical history, physical
             examination, vital signs and 12-lead ECG at screening.

          -  Subjects who had clinical laboratory tests clinically acceptable at screening.

          -  Subjects who were negative for HBsAg, anti-HCV Ab and HIV-1 and HIV-2 Ab tests at
             screening.

          -  Subjects who were negative for alcohol and drugs of abuse at screening.

          -  Subjects who were non-smokers or who smoke less than 10 cigarettes or equivalent per
             day.

          -  Subjects who were able and willing to give written informed consent.

          -  (If female) She was not of childbearing potential by reason of surgery or, if of
             childbearing potential, she used one of the following methods of contraception:
             doublebarrier, intra-uterine device or abstinence.

          -  (If female) She had a negative pregnancy test at screening and admission to each
             study period.

        Exclusion Criteria:

          -  Subjects who do not conform to the above inclusion criteria, or

          -  Subjects who have a clinically relevant history or presence of respiratory,
             gastrointestinal, renal, hepatic, haematological, lymphatic, neurological,
             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,
             dermatological, endocrine, connective tissue diseases or disorders.

          -  Subjects who have a clinically relevant surgical history.

          -  Subjects who have a clinically relevant family history.

          -  Subjects who have a history of relevant atopy.

          -  Subjects who have a history of any drug hypersensitivity.

          -  Subjects who have a history of alcoholism or drug abuse.

          -  Subjects who consume more than 14 units of alcohol a week.

          -  Subjects who have a significant infection or known inflammatory process on screening
             and/or first admission.

          -  Subjects who have acute gastrointestinal symptoms at the time of screening and/or
             first admission (e.g., nausea, vomiting, diarrhoea, heartburn).

          -  Subjects who have used medicines within 2 weeks of admission to first period.

          -  Subjects who have participated in any clinical trial within 3 months prior to
             screening.

          -  Subjects who have previously received BIA 2-093.

          -  Subjects who have donated and/or received any blood or blood products within the
             previous 3 months prior to screening.

          -  Subjects who are vegetarians, vegans and/or have medical dietary restrictions.

          -  Subjects who cannot communicate reliably with the investigation team.

          -  Subjects who are unlikely to co-operate with the requirements of the study.

          -  Subjects who are unwilling or unable to give written informed consent.

          -  (If female) She is pregnant or breast-feeding.

          -  (If female) She is of childbearing potential and she does not use an approved
             effective contraceptive method or she uses oral contraceptives.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CEB - Centre for Bioavailability Studies, AIBILI</name>
      <address>
        <city>Azinhaga de Santa Comba - Celas</city>
        <state>Coimbra</state>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 31, 2014</lastchanged_date>
  <firstreceived_date>October 29, 2014</firstreceived_date>
  <firstreceived_results_date>November 28, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>st period - 16 mL oral suspension 50 mg/mL
nd period - Four 200 mg tablets
rd period - One 800 mg tablet</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>st period - One 800 mg tablet
nd period - 16 mL oral suspension 50 mg/mL
rd period - Four 200 mg tablets</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>st period - Four 200 mg tablets
nd period - One 800 mg tablet
rd period - 16 mL oral suspension 50 mg/mL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>st period - 16 mL oral suspension 50 mg/mL
nd period - Four 200 mg tablets
rd period - One 800 mg tablet</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>st period - One 800 mg tablet
nd period - 16 mL oral suspension 50 mg/mL
rd period - Four 200 mg tablets</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>st period - Four 200 mg tablets
nd period - One 800 mg tablet
rd period - 16 mL oral suspension 50 mg/mL</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - the Maximum Plasma Concentration</title>
        <description>Cmax - the maximum plasma concentration of BIA 2-093 metabolite: BIA 2-005</description>
        <time_frame>Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BIA 2-093 16 mL Oral Suspension 50 mg/mL</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) 16 mL oral suspension 50 mg/mL</description>
          </group>
          <group group_id="O2">
            <title>BIA 2-093 - Four 200 mg Tablets</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) - Four 200 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>BIA 2-093 One 800 mg Tablet</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) - One 800 mg tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax - the Maximum Plasma Concentration</title>
            <description>Cmax - the maximum plasma concentration of BIA 2-093 metabolite: BIA 2-005</description>
            <units>ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18048" spread="4644"/>
                  <measurement group_id="O2" value="16007" spread="4008"/>
                  <measurement group_id="O3" value="17042" spread="4131"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - the Time of Occurrence of Cmax</title>
        <description>Tmax - the Time of Occurrence of maximum plasma concentration of BIA 2-093 metabolite: BIA 2-005</description>
        <time_frame>Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BIA 2-093 16 mL Oral Suspension 50 mg/mL</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) 16 mL oral suspension 50 mg/mL</description>
          </group>
          <group group_id="O2">
            <title>BIA 2-093 - Four 200 mg Tablets</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) - Four 200 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>BIA 2-093 One 800 mg Tablet</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) - One 800 mg tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tmax - the Time of Occurrence of Cmax</title>
            <description>Tmax - the Time of Occurrence of maximum plasma concentration of BIA 2-093 metabolite: BIA 2-005</description>
            <units>hours</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                  <measurement group_id="O2" value="3" lower_limit="1.5" upper_limit="6"/>
                  <measurement group_id="O3" value="3" lower_limit="1" upper_limit="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time</title>
        <description>AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time of BIA 2-093 metabolite: BIA 2-005</description>
        <time_frame>Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BIA 2-093 16 mL Oral Suspension 50 mg/mL</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) 16 mL oral suspension 50 mg/mL</description>
          </group>
          <group group_id="O2">
            <title>BIA 2-093 - Four 200 mg Tablets</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) - Four 200 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>BIA 2-093 One 800 mg Tablet</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) - One 800 mg tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time</title>
            <description>AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time of BIA 2-093 metabolite: BIA 2-005</description>
            <units>ng*h/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="323277" spread="64055"/>
                  <measurement group_id="O2" value="302026" spread="65270"/>
                  <measurement group_id="O3" value="299016" spread="58806"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity</title>
        <description>AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity of BIA 2-093 metabolite: BIA 2-005</description>
        <time_frame>Blood samples for PK assays: pre-dose, 30, 60 and 90 minutes, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BIA 2-093 16 mL Oral Suspension 50 mg/mL</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) 16 mL oral suspension 50 mg/mL</description>
          </group>
          <group group_id="O2">
            <title>BIA 2-093 - Four 200 mg Tablets</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) - Four 200 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>BIA 2-093 One 800 mg Tablet</title>
            <description>BIA 2-093 (ESL, Eslicarbazepine acetate) - One 800 mg tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity</title>
            <description>AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity of BIA 2-093 metabolite: BIA 2-005</description>
            <units>ng*h/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="325732" spread="64898"/>
                  <measurement group_id="O2" value="304219" spread="66045"/>
                  <measurement group_id="O3" value="301065" spread="59957"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BIA 2-093 16 mL Oral Suspension 50 mg/mL</title>
          <description>BIA 2-093, ESL, Eslicarbazepine acetate oral suspension 50 mg/mL</description>
        </group>
        <group group_id="E2">
          <title>BIA 2-093 - Four 200 mg Tablets</title>
          <description>BIA 2-093, ESL, Eslicarbazepine acetate 200 mg tablets</description>
        </group>
        <group group_id="E3">
          <title>BIA 2-093 One 800 mg Tablet</title>
          <description>BIA 2-093, ESL, Eslicarbazepine acetate 800 mg tablet</description>
        </group>
        <group group_id="E4">
          <title>Follow-up</title>
          <description>Follow-up.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (4.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Migraine type headaches</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Localized erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Facial flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
